List of Notable Biotech Companies in Canada by 2025
Top Canadian Biotech Stocks: ME Therapeutics Leads the Pack
In the dynamic world of biotechnology, Canadian companies continue to make significant strides. As of mid-July 2025, ME Therapeutics Holdings (CSE:METX) stands out as the top performer among the top five biotech stocks on the TSX, TSXV, and CSE, based on year-on-year gains.
ME Therapeutics, a company focused on novel cancer therapies, has reported a strong year-on-year gain of 33.33%, a market cap of approximately C$148 million, and a share price of C$5.00 [1]. The company's primary focus is enhancing the efficacy of current immuno-oncology drugs by targeting suppressive myeloid cells.
One of ME Therapeutics' key drug candidates is the antibody h1B11-12, which is designed to inhibit the cytokine G-CSF. Research conducted in collaboration with Dr. Kenneth Harder at the University of BC has demonstrated that G-CSF appears to increase tumor growth in breast and colon cancer, and a correlation between survival in patients with colorectal cancer and low expression of G-CSF [1].
In addition to its drug development efforts, ME Therapeutics is collaborating with NanoVation Therapeutics to develop therapeutic mRNA delivery methods to myeloid cells. This collaboration is supported by funding from the National Research Council of Canada Industrial Research Assistance Program [1]. The company is also exploring a U.S. listing on either the Nasdaq or NYSE.
Another notable Canadian biotech company is NervGen, a clinical-stage firm that focuses on developing innovative treatments to enable the nervous system to repair itself following damage from injury or disease. NervGen's lead drug candidate, NVG-291, is designed to relieve inhibitory effects, promoting nervous system repair. NervGen is currently advancing NVG-291 in a Phase 1b/2a clinical trial for spinal cord injury, and has received fast track designation from the US FDA [1].
While Bright Minds Biosciences (CSE:DRUG), Hemostemix (TSXV:HEM), Eupraxia Pharmaceuticals (TSX:EPRX), and NervGen did not provide detailed updates in the available data, they are also among the top performers in the Canadian biotech sector.
Eupraxia Pharmaceuticals, for example, is a company that focuses on developing locally delivered therapeutics for patients with unmet medical needs, primarily in orthopedics and oncology. The company recently acquired EpiPharma Therapeutics, absorbing its lead candidate EP-104GI, which is under investigation in a Phase 2b study, with top-line results anticipated in Q3 2026 [1].
As the biotech sector continues to evolve, these Canadian companies are at the forefront of innovation, pushing the boundaries of what is possible in the fight against disease and injury.
- In the realm of health-and-wellness and science, ME Therapeutics, a leader in novel cancer therapies, collaborates with NanoVation Therapeutics to leverage technology for developing therapeutic mRNA delivery methods.
- Amidst the advancements in the lifestyle sector, Bright Minds Biosciences, Hemostemix, Eupraxia Pharmaceuticals, and NervGen, focusing on diverse areas such as orthopedics, oncology, and nervous system repair, are making significant strides in the Canadian biotech industry.
